Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY) - Université de Lorraine Access content directly
Journal Articles Gastroenterology Year : 2021

Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)

Abstract

VARSITY (An Efficacy and Safety Study of Vedolizumab Intravenous [IV] Compared to Adalimumab Subcutaneous [SC] in Participants With Ulcerative Colitis) showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab vs adalimumab. This analysis compared histologic outcomes.
ClinicalTrials.gov NCT02497469; EudraCT 2015-000939-33.
No file

Dates and versions

hal-04214563 , version 1 (22-09-2023)

Identifiers

Cite

Laurent Peyrin-Biroulet, Edward Loftus, Jean-Frédéric Colombel, Silvio Danese, Raquel Rogers, et al.. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology, 2021, 161 (4), pp.1156-1167.e3. ⟨10.1053/j.gastro.2021.06.015⟩. ⟨hal-04214563⟩
9 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More